Expert Panel Fails to Reach Consensus on Optimal Clinical Practices for Ketamine and Esketamine Treatments

Psychiatric use of ketamine and esketamine for treatment-resistant depression is expanding, yet clinical consensus remains fragmented.

An international panel of experts, reporting in The Journal of Clinical Psychiatry on November 2, reached agreement on only about one-third of 105 clinical practice statements, highlighting significant uncertainty regarding optimal treatment protocols.

Clinical Realities of Rapid-Acting Antidepressants

The lack of broad consensus does not necessarily signal poor-quality evidence, but rather reflects the evolving nature of these therapies. Gerard Sanacora, MD, PhD, professor of psychiatry and director of the Depression Research Program at Yale University, said that “nonconsensus is itself a finding.”

The task force, which included 21 experts from six countries, utilized a structured Delphi survey to identify where clinical practice aligns with data and where it deviates into uncharted territory.

In Plain English: The Clinical Takeaway

  • Standardized Dosing: Experts largely agree on a 0.5 mg/kg starting dose for IV ketamine, administered over 40 minutes, with little evidence that exceeding 2 mg/kg provides extra benefit.
  • Safety First: There is strong, near-unanimous agreement that these treatments must be administered in a medical facility with proper supervision, not at home.
  • Evidence Gaps: Many common practices—such as using oral lozenges between sessions or specific maintenance frequencies—lack robust data, meaning your treatment plan should be highly individualized.

Areas of Agreement and Clinical Strategy

The panel achieved strong consensus on several critical safety and administration points. For instance, clinicians agreed that patients with active substance use disorders should generally avoid these treatments, while stable, controlled cardiovascular disease is not an automatic disqualifier. The task force also supported the use of ketamine for bipolar depression and suicidal ideation, despite these uses remaining off-label in many contexts.

Clinical Parameter Consensus Status Expert Recommendation
IV Ketamine Starting Dose Strong Consensus 0.5 mg/kg over 40 minutes
At-Home Administration Strongly Opposed Must occur in a clinical facility
Maximum IV Dose Strong Consensus 2 mg/kg (diminishing returns above this)
Maintenance Frequency No Consensus Individualized to lowest effective dose

Unresolved Questions in Psychiatric Practice

The panel failed to reach consensus on whether IV ketamine or intranasal esketamine—the latter of which holds FDA approval for treatment-resistant depression—is superior in efficacy. Uncertainty also surrounds the use of intramuscular injections and the potential benefits of pairing the medication with psychotherapy. Because high-quality, head-to-head randomized controlled trials are currently limited, clinicians are often left to rely on individual clinical judgment rather than established guidelines.

The researchers said "failure to reach consensus often reflected insufficient evidence rather than doubts about efficacy." This gap between the widespread adoption of these drugs and the availability of standardized, large-scale data creates a challenge for practitioners who must balance innovation with patient safety.

Who Should Avoid Ketamine and Esketamine Treatments

Patients should be aware that ketamine and esketamine are not suitable for everyone. Active substance use disorders are generally considered a contraindication, and patients with unstable cardiovascular conditions require rigorous pre-treatment evaluation.

The path forward, according to the panel, involves the creation of a voluntary patient registry to aggregate real-world data. Until such systems are implemented, the clinical use of these agents will continue to be defined by localized practice rather than universal standards. As Sanacora emphasized, the panel’s work was intended to identify exactly which questions require urgent, further investigation through rigorous, adequately powered clinical trials.

References

  • The Journal of Clinical Psychiatry published a consensus statement on ketamine and esketamine for depression online on November 2.
  • U.S. Food and Drug Administration (FDA): Approval status and clinical guidelines for Spravato (esketamine).
  • PubMed/National Library of Medicine: Systematic reviews on the mechanism of action of N-methyl-D-aspartate (NMDA) receptor antagonists in mood disorders.
Photo of author

Priya Deshmukh - Senior Editor, Health

Priya Deshmukh Senior Editor, Health Deshmukh is a practicing physician and renowned medical journalist, honored for her investigative reporting on public health. She is dedicated to delivering accurate, evidence-based coverage on health, wellness, and medical innovations.

JPMorgan Upgrades MSCI Turkey Index to Overweight